Objectives: To investigate whether CCAAT/enhancer-binding protein β (C/EBPβ) mediates expression of matrix metalloproteinase-3 (MMP-3) and aggrecanases in arthritis. Conclusions: These data demonstrate that C/EBPβ is involved in expression of MMP-3 and ADAMTS-5 in arthritic synovium and cartilage. 
INTRODUCTION
Irreversible destruction of cartilage is a feature of arthritis such as rheumatoid arthritis (RA) and osteoarthritis (OA). Inflammation pathways are involved in the catabolic processes of articular cartilage especially in RA and potentially in OA. Proinflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor α (TNF-α) play significant roles in mediating inflammation and joint destruction and have been therapeutic targets. Although the levels of proinflammatory cytokines in OA are generally lower than those in RA [1] , inflammatory reactions are associated with symptoms of OA especially in the early stages of the disease. [2] Stimulation of these cytokines in arthritis activates numerous transcriptional factors and induces expression of matrix metalloproteinases (MMPs), aggrecanases, and other catabolic factors in the synovium, synovial fluids and cartilage, which adversely affects the joint structures including cartilage. [3, 4] Among transcriptional factors activated by proinflammatory cytokines, we focused on the functions of the CCAAT/enhancer binding protein (C/EBP) family in arthritis.
The C/EBP family contains a basic leucine zipper domain and consists of six family members: C/EBPα, β, δ, ε, γ, and ζ. [5] Functions of the C/EBP family include regulation of numerous cellular processes including differentiation, proliferation, control of metabolism, and inflammation. C/EBPβ and/or δ are induced in response to inflammatory stimulation in various tissues. [6] Previous reports describe that C/EBPβ and δ are expressed in synovial tissues of RA and OA. [7, 8] Recent reports suggest that C/EBPβ may act via three catabolic pathways during the development of arthritis. First, C/EBPβ directly enhances inflammatory enzymes. C/EBPβ and/or δ mediate inflammatory genes such as phospholipase A2 and cyclooxygenase-2 in articular cartilage. [9, 10] Second, C/EBPβ regulates extracellular matrix (ECM) synthesis. C/EBPβ and δ repress type I collagen [11] and activate osteocalcin in osteoblasts. [12] Also, C/EBPβ and δ induced by IL-1β mediate the repression of 4 cartilage-derived retinoic acid-sensitive protein (CD-RAP) and Col2α1 promoter activity in chondrocytes. [13] Third, C/EBPβ mediates the expression of catabolic enzymes in arthritis.
MMP-1 is transactivated by C/EBPβ in chondrocytes through IL-1β-stimulated extracellular signal regulated kinase (ERK) activation. [14] A previous report demonstrated that expression of MMP-13 is mediated by C/EBPβ in human chondrocytes in inflammatory arthritis. [15] These findings suggest that C/EBPβ and δ plays important roles in various catabolic processes in arthritis. Further analysis of the functions of C/EBP is important for understanding the pathogenesis of arthritis.
MMPs are known to be important factors in degrading native collagen and proteoglycans and leading to the development of arthritis. Aggrecanases, also known as A Disintegrin And Metalloproteinase with ThromboSpondin type 1 motifs (ADAMTS), are proteolytic enzymes that are responsible for cleavage of the proteoglycan aggrecan. In humans, aggrecanase-1 (ADAMTS-4) and aggrecanase-2 (ADAMTS-5) are considered to be major contributors to the development of OA. [16, 17] Matrix metalloproteinase 3 (MMP-3)
is also highly expressed in synovial cells and chondrocytes of inflammatory arthritis. [18, 19] MMP-3 has a variety of substrate specificities and degrades proteoglycans, collagen types III, IV, IX and XI, gelatin, laminin, and fibronectin. [20] Furthermore, MMP-3 can activate procollagenases MMPs-1, -8, and -13. [21] When OA was experimentally induced in MMP-3 knock-out mice, there was a 67% reduction in the occurrence of severe cartilage damage when compared with control mice. [22] In clinical practice, serum levels of MMP-3 are used as a marker for predicting disease activity and progression in RA and potentially in OA. [23, 24] Thus, MMP-3 plays a pivotal role in the pathological destruction of cartilage in both RA and OA.
In this paper, we investigated the functional involvement of C/EBPβ for regulating catabolic enzymes, specifically MMP-3 and ADAMTS-5, in synovium and 
MATERIALS AND METHODS
Detailed methods are described in the online supplement. [antisense]. siRNA-2 target sequence,
[antisense]) or negative control siRNA were purchased (Ambion). Transfection mixes were prepared using Lipofectamine RNAiMAX (Invitrogen) with control or target-specific siRNA and applied to cells. Cells were cultured for 24 hours after transfection. Transfected SW982, HFLS and C28/I2 cells were treated with 10 ng/ml IL-1β for 24 hours, 10 ng/ml IL-1β for 24
hours, and 2 ng/ml IL-1β for 5 hours, respectively. 
DISCUSSION
In this study, we demonstrated that the transcription factor C/EBPβ promotes MMP-3 expression in arthritic synovial membrane and cartilage tissue. Alteration of MMP-3 expression by gain and loss of function of C/EBPβ was most significant, suggesting that C/EBPβ is one of the main regulators of MMP-3 expression. Furthermore, this study also suggests that C/EBPβ regulates, at least in part, ADAMTS-5, which is also a crucial enzyme 12 in degrading cartilage in OA. These findings suggest that C/EBPβ plays crucial roles in cartilage degradation through production of various catabolic enzymes in synovium and cartilage in RA and OA. In addition, we performed experiments in relation to CEBPδ.
Promoter assay and treatment with siRNA for C/EBPδ indicated that C/EBPδ is also involved in cartilage degradation by production of IL-6, MMP-3 and ADAMTS-5, whereas the contribution of C/EBPδ may be weaker than that of C/EBPβ. C/EBPδ may play compensatory role for C/EBPβ in the catabolic processes in arthritis.
In inflammatory arthritis, particularly in RA, synovitis is thought to be a key player in pathogenesis. In contrast, the pathogenesis of OA may originate from cartilage and the cartilage degradation may induce secondary synovitis. However, recently the concept of synovial inflammation contributing to OA pathology particularly in early disease has been emphasized. [4] Immunohistochemical staining in this study showed that C/EBPβ was expressed in synovial tissues regardless of arthritis type (RA or OA). These findings suggest that C/EBPβ is a common proinflammatory factor in arthritic synovial tissues, which profoundly affects degradation of cartilage. As previously described, MMP-3 is highly expressed in both RA and OA synovium, which is a potent activator of tissue procollagenases. Aforementioned in introduction, MMP-3 knock-out mice demonstrating the importance of this matrix-degrading enzyme in an animal model of OA. [22] However, the relevance of MMP-3 in RA is far to be clear since the same MMP-3 knock-out mice normally develop arthritis. [32] This report indicated that MMP-3 is one of important catabolic factors, whereas only inhibition of MMP-3 is insufficient to inhibit the cartilage degradation. Joint destruction results from multiple matrix-degrading enzymes such as other MMPs and ADAMTSs. MMP-13 and ADAMTS-5 also exist in the synovial tissue of arthritis. [33] [34] [35] Therefore, the regulation of these catabolic factors by C/EBPβ in the synovium may be important for the pathogenesis of RA and OA. Our data indicate that C/EBPβ regulates ADAMTS-5 expression particularly in chondrocytes. The molecular mechanism involving expression of ADAMTS-5 remains unclear. Examination of the human ADAMTS-5 promoter suggests that it is regulated by runt-related transcription factor-2 (RUNX2), [39] which is a protein known to be expressed in OA. RUNX2 is required for chondrocyte hypertrophy in the development of OA. [40] C/EBPβ also promotes hypertrophic differentiation of chondrocytes.
[37] There is increasing evidence to suggest that C/EBPβ acts as a co-activator of RUNX2 on several down-stream targets. Indeed, the osteocalcin promoter is up-regulated by co-activation of C/EBPβ and RUNX2. [12] We found potential C/EBPβ binding motifs in the ADAMTS-5 promoter
14
(-1517 to -1509), which is located next to the RUNX2 responsive motifs previously reported. [39] In fact, the CHIP assay showed that C/EBPβ binds the ADAMTS-5 promoter region between -1648 bp and -1365 bp. Therefore, it is conceivable that C/EBPβ interacts with RUNX2 and synergistically activates ADAMTS-5 expression in arthritis leading to degradation of cartilage.
In conclusion, C/EBPβ is considered to play two major roles in arthritis. One role promoter deletion constructs were co-transfected with pCMV-LAP or GFP into C28/I2 cells.
Relative luciferase activity was assayed 24 hours post-transfection. D, Site-directed mutagenesis of the human MMP-3 promoter and luciferase reporter assay. The promoter
